• AIM: To investigate the retinal toxicity and pharmacokinetics of simvastatin intravitreally injected into mice.
INTRODUCTION

S
tatins, potent inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, have widely been prescribed for the treatment of hyperlipidemia since 1987 [1] and have recently been demonstrated to possess an expanding spectrum of activities, including anti-inflammatory, anti-angiogenic, anti-oxidant [2] , immunosuppressive [3] and neuroprotective [4] [5] [6] effects. Statins have been reported to be beneficial to patients with a variety of ocular diseases such as diabetic retinopathy [7] , age-related macular degeneration (AMD) [8] and retinal ischemia and to potentially be useful in glaucoma [9] [10] [11] [12] . Simvastatin, the semisynthetic statin tested in the present study, is one of the most potent of all the identified statins; simvastatin inhibits the diabetes-induced increases in vascular endothelial growth factor (VEGF) expression, protects the blood-retinal barrier and suppresses the progression of streptozotocin-induced diabetic retinopathy in rats [13] [14] [15] . A recent study has shown that simvastatin activated the anti-oxidative defense protein HO-1 in cultured human retinal pigment epithelial (RPE) cells [16] and that this activity contributed to its cytoprotective effect against AMD. Considering the potential adverse side effects of intravitreally-injected steroids [e.g. intraocular pressure (IOP) elevation, cataract] and anti-VEGF drugs (e.g. intolerance, cost, and unknown deleterious cumulative systemic effects) commonly used in the treatment in AMD or diabetic retinopathy, simvastatin might be a potential alternative drug candidate as several reports have suggested that simvastatin inhibits the progression of these two diseases [17] [18] [19] [20] . It has also been shown that simvastatin enhanced retinal ganglion cell (RGC) survival and protected visual functions in rodent models of acute retinal ischemia/ reperfusion injury [21] [22] [23] and optic nerve lesioning [24] . Simvastatin inhibits the Rho/Rho-kinase pathway and thus might have therapeutic potential in the prevention of cicatrical contraction of proliferative membranes in vivo study. And thus, simvastatin might provide a new strategy for the treatment and prevention of the development of proliferative vitreoretinal diseases [25] .
In most of the literature, statins were administered orally or injected intraperitoneally. From a clinical perspective, some ocular conditions would be better managed if the intraocular statin concentration was increased more efficiently via direct intravitreal injection; such conditions include when ocular conditions are acute or when systemic side effects should be avoided [26] [27] . From a research perspective, intravitreal injection is superior to systemic delivery routes because the other eye can serve as an internal control in certain experimental settings [28] . Our objective was to study the retinal toxicity of simvastatin to mice using electroretinography (ERG) and electron microscopy. These results are pivotal in guiding future laboratory and clinical studies on the dosage and delivery of simvastatin. This study is particularly relevant to mouse research models, as such disease models are widely available and are easily combined with genetic manipulations or surgical interventions [29] . The long-term goal of this line of investigation is to utilize mouse models to investigate the potential neuroprotective effects of simvastatin against avariety of retinal diseases such as glaucoma and AMD [30] [31] [32] .
MATERIALS AND METHODS
Animal Preparations
Forty-eight 6-8 weeks old C57BL/6J mice obtained from the Jackson Laboratory (Bar Harbor, ME, USA) were used for the experiments. The animals were treated in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and with the animal welfare guidelines of the IACUC of Baylor College of Medicine. Intravitreal Injection Because vitreal simvastatin concentrations of 5 and 15 μmol/L have been shown to be effective and did not produce sign of toxicity in previous animal studies [24] [25] , we selected higher vitreal simvastatin concentrations of 50 and 200 μmol/L for this retinal toxicity study to provide at least 10× margin over the previous studies. Simvastatin (#S6196, Sigma-Aldrich Corp. St. Louis, MO, USA) was converted to its active form according to the manufacturer's instructions [33] , diluted in sterile buffered balanced salt solutions (pH 7.5; Alcon Laboratories, Inc., Fort Worth, TX, USA), and then filtered using a 0.22-μm PVDF filter (Millipore, Billerica, MA, USA). Aliquots were stored at -20℃ before use. The mice were first anesthetized by intraperitoneally injecting weight-based doses of ketamine (95 mg/mL) and xylazine (5 mg/mL). Then, a single drop of 0.5% proparacaine hydrochloride (Alcon Laboratories, Inc., Fort Worth, TX, USA) and 1% tropicamide were applied to both eyes. One microliter of 0.5 or 2.0 mmol/L simvastatin was injected into the vitreous of the right eye under a stereomicroscope using a Nanofil syringe fitted with a 33-gauge beveled needle (WPI, Sarasota, FL, USA). One microliter of an equivalent vehicle solution was injected into the left eye as a control. Assuming that the injected 1 μL of solution was diluted into the 10 μL of vitreous fluid in the eye [34] [35] , the vitreal concentrations of simvastatin were 50 and 200 μmol/L for the injected 0.5 and 2.0 mmol/L solutions, respectively. The needle was inserted behind the limbus through the pars plana at an oblique angle to avoid damaging the crystallized lens. To prevent the injected solution from escaping the eye when the needle was withdrawn, the needle tip was held in the eye for 30s after the injection to facilitate mixing. Electroretinography Recordings In vivo scotopic ERG was recorded bilaterally from the mice 1 and 7d after intravitreal injection. A pre-injection measurement was performed on a different cohort of mice as a reference. Prior to each ERG assessment, the mice were allowed to adapt to the dark for at least 2.5h. Under dim redlight, the mice were prepared for ERG testing as described previously [30] . The signals were amplified using a Grass P122 amplifier and were bandpass filtered from 0.1 to 1000 Hz (Grass Instruments, West Warwick, RI, USA). The data were acquired using a National Instruments data acquisition board (USB-6216, National Instruments, TX, USA) at a sampling rate of 10 kHz. The traces were analyzed using custom codes written in MATLAB (MathWorks, Natick, MA, USA) [30] . The flashes used for scotopic b-wave measurements were generated using cyan light-emitting diodes calibrated with a photometer (ILT1700, International Light, MA, USA) and were converted to the unit photoisomerizations/rod, where 1 scot cd m 2 =581 photoisomerizations/rod/s [30] . To remove oscillatory potentials before fitting, the scotopic b-wave was digitally filtered using the filtfilt function in MATLAB (lowpass filter; Fc=60 Hz). The positive and negative scotopic threshold responses (STRs) were measured under stimuli of various intensities as described previously [30] . The cone ERG recording was performed according to a paired-flash method using xenon flashes [36] . An initial conditioning flash saturated both rods and cones 2s before a probe flash. The ERG signal recorded by the probe flash is attributed to responses driven by the cones because cones recover faster than rods. In this manuscript, the stimulus intensities are presented on a log scale, where 1E+0=1 photoisomerizations/rod. All statistical analyses were performed using paired t-tests in SPSS version 20 (IBM). Pharmacokinetic Analysis via High-performance Liquid Chromatography The ocular concentration of simvastatin in the current study was measured using the retinal tissue instead of the vitreous humor, which is commonly used in rabbit pharmacokinetic models [37] [38] [39] . This experimental approach is advantageous because the retina itself is typically the target of treatment.
The injected eyes were enucleated at 1, 3, 6, 12, 24 or 48h to measure the retinal concentration of the drug. For each of the above time points, at least three microcentrifuge tube samples were analyzed. Each sample contained four whole retinae extracted from four eyes. First, 100 μL of phosphate buffered saline (PBS) at 4℃ was added to the sample before the samples were homogenized using amotorized mortar (#47747-370, VWR International LLC, Radnor, PA, USA) for a total of 6min. Then, 900 μL of acetonitrile at 4℃ was added to the sample. The mixture was subsequently vortexed for 2min and then ultra-centrifuged at 68 000× g for 20min at 4℃. The supernatant was transferred to auto-sampler vials and then concentrated to a volume of 50-80 µL using a SpeedVac. The resulting samples contained 50% acetonitrile and 0.1% (v/v) trifluoroacetic acid (TFA).
The simvastatin standards (Sigma-Aldrich Corp., St. Louis, MO, USA) were dissolved in 100 μL of 50% acetonitrile containing 0.1% (v/v) TFA and were vortexed for 1min. All samples were filtered through a 0.45 μm Acrodisc ® 3 CR PTFE filter to remove insoluble particles before injection into a C18 high-performance liquid chromatography (HPLC) column (Grace Davison Discovery Sciences, 4.6×250 mm, 5-micron, Vydac 218TP C18). The samples were analyzed using Shimadzu gradient HPLC (Shimadzu Co., Kyoto, Japan) in a system of 0.1% aqueous TFA (buffer A) versus 0.1% TFA in acetonitrile (buffer B) at a flow rate of 1 mL/min. A 100 μL volume of each sample was injected into the C18 column, which was pre-equilibrated with 50% buffer B. Simvastatin was eluted with a two-step gradient of acetonitrile: 50% acetonitrile containing 0.1% TFA for 10min followed by 80% acetonitrile containing 0.1% TFA for an additional 10min. Simvastatin was monitored by measuring the absorbance at 238 nm using a Shimadzu SPD-M20A UV/ VIS photodiode array detector (Shimadzu Co.) interfaced to a computer running Shimadzu LCsolution software. The standard curve, which was created using eight different concentrations of the simvastatin standard, was linear from 2 to 640 pmol (correlation coefficient 0.99988). The detection limit using this method was estimated to be approximately 1.5 pmol (signal-to-noise ratio greater than 2). Pharmacokinetic data were then analyzed using Phoenix WinNonlin software version 5.3 (Certera, St. Louis, MO, USA).
The following equation was used for the one-compartment model:
where C(t) denotes the quantity of simvastatin at time t, V d denotes the volume of distribution, and K(h -1 ) denotes the elimination rate constant. In addition, data were analyzed using a non-compartmental model for reference.
Retinal Histology On the 7 th day following injection, anesthetized mice were euthanatized via cervical dislocation, and their eyes were enucleated after ERG recording was conducted. For histologic studies, a large full-thickness incision was made in the cornea, and the anterior segment was removed. Then, the eye cups were fixed in 3% glutaraldehyde in phosphate buffer. The tissue was then washed in 1 mol/L sodium phosphate buffer, pH 7.3, and post-fixed in 1% osmium tetroxide for 1h at room temperature. The dehydrated tissue was infiltrated with acetone and Poly/Bed 812 plastic resin. The tissue was then embedded in plastic block molds with 100% Poly/Bed 812. Sections (1 μm thick) were generated on an ultramicrotome, placed on glass slides and stained with toluidine blue for light microscopy. The areas of interest were trimmed, and 80-nm-thick ultra-thin sections were sliced using a Leica Ultracut R Ultramicrotome, mounted on 100-mesh copper grids, and stained with 2% uranyl acetate and Reynold's lead citrate. The specimens were imaged using a Zeiss CEM 902 electron microscope to study the retinal ultrastructure. For immunohistochemistry (IHC) and cell counting studies, the eyes were carefully dissected to isolate whole retinae, which were then incubated in 4% [40] . Photoreceptor nuclei in the outer retina and ganglion cell nuclei in the inner retina were stained using the fluorescent nuclear dye TO-PRO3 [41] . Cone cell bodies were immunolabeled with a rabbit antibody against GNAT2 (1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA, Cat. No. SC-390) [42] [43] . The dimensions were measured using built-in tools in Zeiss LSM software. To determine whether injection of 200 μmol/L simvastatin produced any toxicity to the retina and caused any retinal cell loss, the thicknesses of the two retinal nuclear layers were gauged, and the numbers of cone soma, rod bipolar cells and ganglion cells were systematically counted in the two groups. Five mice, each of which received injections of 200 μmol/L simvastatin into one eye and vehicle solution into the other eye, were sacrificed. Three sections from each eye were imaged, for a sample size of 15 per group; the number of cells in each 200-μm region were counted, and the dimensions were measured. RESULTS Electroretinography Changes in the amplitudes of the scotopic a-wave and b-wave against an increasing stimulus intensity measured 1 and 7d after injection of 50 or 200 μmol/L simvastatin are shown in Figure 1 . As shown in panels A-D, eyes injected with either 50 or 200 μmol/L simvastatin showed no significant differences in the a-or b-waves at 9 stimulus intensities 1 or 7d after injection on ERG compared to the control eyes. Baseline a-wave and b-wave responses from another 7 pairs of eyes before injection are shown in panel E for reference. To test whether simvastatin produced any toxicity to the retinal cone pathway, we employed paired flash ERG recordings to isolate the cone-driven responses from the rod-driven responses. As shown in Figure 2 , there were no significant differences in the cone a-wave or b-wave between the simvastatin-injected eyes and the vehicle-injected control eyes based on ERG recordings performed 1 and 7d after injection (7 pairs of eyes). Figure 3 shows the changes in the positive STRs (pSTRs) and the negative STRs (nSTRs) in response to increasing stimulus intensities 1 and 7d after injection of 50 or 200 μmol/L simvastatin. There were no significant differences in the mean pSTR or nSTR between simvastatininjected eyes and control eyes for either concentration at each time point. Given that the pSTR and the nSTR represent inner retinal signaling from third-order neurons such as RGCs and AII amacrine cells [44] [45] [46] , our results suggest that a vitreal simvastatin concentration of 200 μmol/L or less does not alter the electrophysiological functions of ganglion cells. Pharmacokinetic Analysis The peak simvastatin concentration was calculated according to appropriate standard curves using LCsolution software. These standard curves, created using eight different concentrations of simvastatin, were linear from Email:ijopress@163.com 0 to 640 pmol (correlation coefficient >0.99988). The detection limit was below 2 pmol. Simvastatin was detectable in retinal samples collected 1h following the injection. Samples collected at the subsequent post-injection time points showed decreasing concentrations of simvastatin. These findings suggest that intravitreally injected simvastatin arrives at the retina shortly after injection; additionally, simvastatin reached its maximum concentration within 1h. The change in the mean simvastatin concentration in the retina over time as measured using HPLC was fitted using a one-compartment model (Figure 4) . The half-lives of simvastatin for injected two concentrations of 200 and 50 µmol/L were found to be 1.92 and 2.41h, respectively ( [47] . Low magnification histologic examination via light microscopy conducted 7d after injection revealed normal neurosensory retinae. No signs of inflammation-or toxicity-induced changes in any retinal layer were found. There were no observable differences in layer thicknesses or cell morphologies between the simvastatin-injected retinae and the control retinae ( Figure 6 ). High magnification histologic examination of individual retinal layers via electron microscopy revealed very similar ultrastructure and cell morphologies between the simvastatininjected retinae and the control retinae ( Figure 7) . No abnormalities in photoreceptors, bipolar cells or ganglion cells were identified in the simvastatin-injected eyes 7d after injection. DISCUSSION Simvastatin has been suggested to have a pleiotropic protective effect against a variety of ocular diseases, including diabetic retinopathy, AMD, retinal ischemia and glaucoma. More recently, its protective effect against glaucomatous neuronal damage has been hypothesized to be related to its antiinflammatory properties [11] . However, the ocular toxicity and pharmacokinetics of simvastatin had not been adequately studied previously. In the present study, we have shown that intravitreal injection of up to 200 μmol/L simvastatin produced no apparent adverse effects in the mouse retina based on results from functional tests via ERG and histologic examinations via fluorescence and electron microscopy. ERG is a useful tool for evaluating retinal functions both experimentally and clinically. In the present study, ERG was performed using a comprehensive range of stimuli to assess the functions of a comprehensive range of retinal neurons. Depending on the stimulus intensity, the a-wave and the b-wave are generated via the rod pathway, the cone pathway or a combination of the two. The scotopic a-wave and b-wave data suggest that simvastatin up to a vitreal concentration of 200 μmol/L does not influence the functions of rod photoreceptors or rod-driven bipolar cells. There were no significant differences in the cone a-wave or b-wave between the simvastatin-injected eyes and the control eyes. This observation indicated that a vitreal simvastatin concentration of 200 μmol/L did not produce any signs of toxicity to the retinal cone pathway. The pSTR and the nSTR are the most sensitive components of the ERG, and our results suggest that a vitreal simvastatin concentration of 200 μmol/L or less does not alter the electrophysiological functions of ganglion cells. Traditionally, statins are administered systemically via oral ingestion, subcutaneous injection, or intraperitoneal injection. In contrast, delivery via intravitreal injection has not been commonly used but has the advantage of enabling the application of a higher dose intraocularly and monocularly within a short interval. Intravitreal injection is also likely to be more efficient when the therapeutic target site is located at the proximal retina, where drugs administered systemically moving from the choroid must overcome diffusion barriers to reach the retina. One successful application of simvastatin was that intravitreally administered 15 μmol/L simvastatin had no apparent adverse effects in rabbits and prevented the progression of induced proliferative vitreoretinopathy [25] . We found that the ocular half-life of simvastatin in the retina following intravitreal administration was 1.92-2.41h; this half-life is relatively short compared with that of other drugs administered via intravitreal injection. For example, the halflives of dexamethasone and triamcinolone were previously reported to be 3.48h and 1.57d, respectively [37] [38] . We cannot directly compare those findings to the present results because the previous studies performed measurements on the rabbit eye. We did not find any related data using mice. In the present study, the HPLC data suggested that intravitreally injected simvastatin rapidly reached the retina and had a short retinal half-life. Our findings indicate that a sustained release mechanism such as an intravitreal implant [48] would be needed to extend the application of simvastatin to the treatment of chronic vitreal-retinal diseases.
Since the calculated half-life is about 2h and simvastatin is mostly cleared in 12h, the 1d time point is appropriate to evaluate acute toxicity and the 1wk time point was designed to evaluate delayed damages, for example, those resulted from inflammation or secondary degeneration. Our results have further shown that administering up to 200 μmol/L simvastatin via intravitreal injection produced no apparent adverse effects on the retinal ultrastructure of mouse eyes, as the retinae showed no signs of anomalies one week after injection. Therefore, a vitreal simvastatin concentration between 50 and 200 μmol/L would be a reasonable starting point for future therapeutic trials using mouse models of acute ocular diseases. Though the weakest point of this study is that the volume of the mouse vitreous is much smaller than that of the human vitreous, the present study is the first to assess the toxicity of simvastatin in mice, which represent a very useful model animal because of their potential for genetic modification and the wide availability of mouse models of disease. This study represents an important step in the exploration of the full potential benefits of simvastatin to patients with ocular disorders, including diabetic retinopathy, AMD, retinal ischemia, glaucoma and proliferative vitreoretinopathy. Intravitreal injection of simvastatin is a highly efficient route of delivery, but the half-life of intravitreally injected simvastatin is relatively short. To extend its application to the treatment of chronic ocular disorders, a slow-release drug delivery system or vehicle might be necessary to sustain a therapeutic simvastatin dosage in the retina.
